Biomarker & Intervention Discovery
Ankylosing Spondylitis / Axial Spondyloarthropathy
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionProgressive structural damage (sacroiliac fusion, syndesmophytes) in majority without treatment; spontaneous…
Best-intervention remissionTNF inhibitors (infliximab, adalimumab): ASAS20 response in 60-70%, clinical remission (ASDAS-ID) in 20-40%; IL-17…
Gap sizeLarge — most patients spend years on NSAIDs before biologic assessment; diagnostic delay averages 7-10 years
Primary barrierpractice/access
Full remission profile →
Remission & chronicity
Spontaneous remission
Progressive structural damage (sacroiliac fusion, syndesmophytes) in majority without treatment; spontaneous radiographic remission essentially zero; ~10% achieve clinical remission without anti-inflammatory therapy
Best-intervention remission
TNF inhibitors (infliximab, adalimumab): ASAS20 response in 60-70%, clinical remission (ASDAS-ID) in 20-40%; IL-17 inhibitors (secukinumab, ixekizumab): equivalent or superior efficacy; remission rates with early biologics in non-radiographic axSpA may reach 40-50%
Gap size
Large — most patients spend years on NSAIDs before biologic assessment; diagnostic delay averages 7-10 years
Primary barrier
practice/access
Diagnostic delay of 7-10 years from symptom onset is the most significant modifiable factor; MRI-based diagnosis of nr-axSpA (non-radiographic) can enable earlier biologic initiation before structural damage; HLA-B27 testing remains underused in primary care assessment of inflammatory back pain
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Ankylosing Spondylitis / Axial Spondyloarthropathy” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."